Pharvaris director reports initial share holdings

Pharvaris N.V. director Elisabeth Bjork filed an initial ownership report detailing her equity position in the company.

Rhea-AI Filing Summary

Pharvaris N.V. director Elisabeth Bjork filed an initial ownership report detailing her equity position in the company. She directly holds 15,167 shares of common stock, along with several stock option awards and restricted stock units granted under the company’s equity plan.

Her option holdings cover common shares at exercise prices of $8.05, $14.39, $18.14, $22.31, $16.05, and $28.00, with expiration dates ranging from 2032 to 2036. Footnotes explain that vesting schedules vary by grant, with one award vesting 100% on its 12‑month anniversary and others vesting 25% initially, then in monthly installments. The report also notes 5,500 restricted stock units from an award granted March 3, 2026, which are scheduled to vest in full on March 3, 2027 and settle in common shares.

Insider Trade Summary

7 transactions reported

Mixed 7 txns

Insider Bjork Elisabeth

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 119,000 contracts (Direct); Common Stock — 15,167 shares (Direct)

Footnotes (5)

1. F1. Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -5,500 RSUs from an award granted March 3, 2026 of which 100% will vest March 3, 2027.
2. F2. 100% of the option vest on the 12-month anniversary.
3. F3. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.
4. F4. 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.
5. F5. 25% of the option vested on January 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Pharvaris (PHVS) director Elisabeth Bjork report in this Form 3?

Elisabeth Bjork reports her initial ownership in Pharvaris, including 15,167 common shares plus multiple stock option awards and restricted stock units. The filing outlines strike prices, expiration dates, and vesting schedules for these equity incentives.

How many Pharvaris (PHVS) common shares does Elisabeth Bjork directly hold?

She directly holds 15,167 shares of Pharvaris common stock. This direct ownership is reported separately from her stock option awards and restricted stock units, which, if vested and exercised, could increase her effective economic exposure to Pharvaris.

What stock options are disclosed for Pharvaris (PHVS) director Elisabeth Bjork?

She holds stock options over Pharvaris common shares with exercise prices of $8.05, $14.39, $18.14, $22.31, $16.05, and $28.00. These options have expiration dates between 2032 and 2036 and follow different time‑based vesting schedules.

What are the key vesting terms for Elisabeth Bjork’s Pharvaris (PHVS) options?

Some options vest 25% on a specific date, with the remainder vesting in 1/48 monthly installments. Another option vests 100% on the 12‑month anniversary of the grant, creating a mix of cliff and gradual vesting across her awards.

What restricted stock units (RSUs) does Elisabeth Bjork hold in Pharvaris (PHVS)?

She holds 5,500 restricted stock units from an award granted March 3, 2026. According to the disclosure, 100% of these RSUs will vest on March 3, 2027 and will settle in Pharvaris common shares upon vesting.

Does this Pharvaris (PHVS) Form 3 show any insider buying or selling activity?

No buy or sell transactions are reported; the entries are holdings. The Form 3 functions as an initial snapshot of Elisabeth Bjork’s existing Pharvaris equity interests, including common shares, stock options, and restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 02:23 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bjork Elisabeth

(Last) (First) (Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	15,167(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	03/03/2027(2)	03/03/2036	Common Stock	16,500	$28	D
Stock Option (Right to Buy)	03/12/2026(2)	03/12/2035	Common Stock	15,000	$16.05	D
Stock Option (Right to Buy)	04/11/2026(2)	04/11/2034	Common Stock	14,000	$22.31	D
Stock Option (Right to Buy)	(3)	04/06/2033	Common Stock	21,000	$8.05	D
Stock Option (Right to Buy)	(4)	04/01/2032	Common Stock	17,500	$18.14	D
Stock Option (Right to Buy)	(5)	01/01/2032	Common Stock	35,000	$14.39	D

Explanation of Responses:

1. Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -5,500 RSUs from an award granted March 3, 2026 of which 100% will vest March 3, 2027.

2. 100% of the option vest on the 12-month anniversary.

3. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.

4. 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.

5. 25% of the option vested on January 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.

	/s/ Marnus Nel, Attorney-in-Fact for Elisabeth Bjork	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)